Lead team presentation
Overall survival in the ITT population and by subgroup. a Kaplan-Meier... | Download Scientific Diagram
Final analysis of progression-free survival in the PALOMA-3 study... | Download Scientific Diagram
2021 Update on Systemic Therapy for Breast Cancer | Published in healthbook TIMES Oncology Hematology
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up | SpringerLink
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer - Gelmon - 2020 - The Breast Journal -
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer | PLOS ONE
PALOMA-2: Final OS - Slideset Download - Clinical Oncology 2022 | CCO
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer | npj Breast Cancer
PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib | npj Precision Oncology
![ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR](https://cdn.koreabiomed.com/news/photo/202206/13831_14395_1052.jpg "ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR")
ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients | SpringerLink
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Lead team presentation
Effectiveness and safety of Palbociclib as first-line treatment in advanced breast cancer - ILAPHAR | Revista de la OFIL
Yara Abdou, MD on Twitter: "PALOMA-2: OS update ❗️Palbo+ET did NOT significantly improve OS compared to PBO+ET ❓Is there a difference btw CDK4/6i ⚠️Interpret with caution given missing survival data and distinct
Japanese patients in PALOMA-2: swimmer plot of subsequent therapy in... | Download Scientific Diagram
![ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR](https://cdn.koreabiomed.com/news/photo/202206/13831_14394_912.jpg "ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR")
ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR
Comparative effectiveness of first line palbociclib plus letrozole vs. letrozole alone for hormone-receptor positive metastatic breast cancer in real world clinical practice - BJMO
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3 -
Ribociclib Improves Survival in Advanced Breast Cancer - NCI
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer - Gelmon - 2020 - The Breast Journal -
